Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma

References

• Forssen E. A., Coulter D. M., Proffitt R. T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Research 1992; 52: 3255–3261
   PubMed Web of Science ®Google Scholar
• Forssen E. A., Male-Brune R., Adler-Moore J. P., Lee M. J., Schmidt P. G., Krasieva T. B., Shimizu S., Tromberg B. J. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue. Cancer Research 1996; 56: 2066–2073
   PubMed Web of Science ®Google Scholar
• Gill P. S., Wernz J., Scadden D. T., Cohen P., Mukwaya G. M., Rose M. E. Lack of cardiac toxicity of liposomal encapsulated daunorubicin (DaunoXome) after long term use in AIDS-related Kaposi's sarcoma. (1996) Proc 9^th NCI-EORTC symposium in new drugs in cancer therapy 1996, (abstract #496)
   Google Scholar
• Gray A., Morgan J. Liposomes in haematology. Blood Rev 1991; 5: 258–272
   PubMed Web of Science ®Google Scholar
• Richardson D. S., Kelsey S. M., Johnson S. A., Tighe M., Cavenagh J. D., Newland A. C. Early evaluation of liposomal daunorubicin (DaunoXome) in the treatment of relapsed and refractory lymphoma. Investigational New Drugs 1997; 15: 247–253
   PubMed Web of Science ®Google Scholar
• Pouna P., Bonoron-Adele S., Gouverneur G., Tariosse L., Besse P., Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. British Journal of Pharmacology 1996; 117: 1593–1599
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Wiemik P. H., Leaf A., Dutcher J. P. Infusional cyclophosphamide, doxorubicin and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favouring infusional administration of chemotherapy. Journal of Clinical Oncology 1993; 11: 1071–1079
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Dekker A. W., De Gast G. C., van Kempen M. L., Lokhorst H. M., Nieuwenhuis H. K. Salvage therapy with ProMace-MOPP followed by intensive chemo-radiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. Journal of Clinical Oncology 1992; 10: 1949–1954
   PubMed Web of Science ®Google Scholar
• Han T., Ezdinli E. Z., Shimaoka K., Desai D. V. Chlorambucil versus combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukaemia. Cancer 1973; 31: 502–508
   PubMed Web of Science ®Google Scholar
• Idestrom K, Kimby E, Bjorkholm M. Treatment of chronic lymphocytic leukaemia and well differentiated lymphocytic lymphoma with continuous low or intermittent high-dose prednimustine versus chlorambucil/prednisolone. European Journal of Cancer 1986; 18: 1117–1121
   Web of Science ®Google Scholar
• Liepman M., Votaw M. L. The treatment of chronic lymphocytic leukaemia with COP chemotherapy. Cancer 1978; 41: 1649–1664
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Flinn I. W., Goodman S., Post L., Jamison J., Miller C. B., Gore S., Diehl L., Willis C., Ambinder R. F., Byrd J. C. Liposomal daunorubicin and CVP: A well tolerated regimen for lymphoma with little non-haematologic toxicity. Blood 1998; 92: 4011, (suppl. 1) (abstract)
   Google Scholar
• Nikitin E. A., Iahnina E. I., Pivnik A. V., Medvedev P. V., Marjin D. S., Astsaturov I. A. Treatment of primary aggressive lymphoma with liposomal daunorubicin (DaunoXome) substitution in CHOP regimen. Blood 1997; 90: 3978, (suppl. 1) (abstract)
   PubMed Web of Science ®Google Scholar
• Cheeson B. D., Horning S. J., Coiffier B., Shipp M. A., Fisher R. I., Connors J. M., Lister T. A., Vose J., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N. L., Armitage J. O., Carter W., Hoppe R., Canellos G. P. Report of an International Workshop to standardise response criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology 1999; 4: 1244–1253
   Google Scholar
• Keating M. J., Kantarjiian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: A new agent with major activity against chronic lymphocytic leukaemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• McBride N. C., Ward M. C., Mills M. J., Eden A. G., Hughes A., Cavenagh J. D., Lament A., Newland A. C., Kelsey S. M. Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to Beam high dose chemotherapy and PBSCT. Leukaemia and Lymphoma 1999; 35: 339–345
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., McLaughlin P., Tucker S., Hagemeister F. B., Swan F., Rodriguez M. A., Romaguera J., Rubenstein E., Cabanillas F. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. Journal of Clinical Oncology 1994; 12: 1169–1179
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F. B., Redman J. R., Barlogie B. Effective salvage therapy for lymphoma with ciplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1998; 71: 117–122
   Google Scholar
• McLaughlin P., Hagemeister F. B., Romaguera J. E., Sarris A. H., Pate O., Young A., Swan F., Keating M., Cabinillas F. Fludarabine, Mitoxantrone and Dexamethasone: An effective new regimen for indolent lymphoma. Journal of Clinical Oncology 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Demetri G. D., Geiger E. A., Xu G., Stefanowicz L., Joyce R., Richardson P., Elias A. D. Outpatient tolerability of high-dose liposome-encapsulated Daunorubicin (DaunoXome) with filgrastim support in patients with solid tumours. 10^th NCI-EORTC symposium in new drugs in cancer therapy. Amsterdam 1998, (abstract #490)
   Google Scholar